CN104274746A - Pharmaceutical composition for treating pharyngitis - Google Patents
Pharmaceutical composition for treating pharyngitis Download PDFInfo
- Publication number
- CN104274746A CN104274746A CN201410539047.5A CN201410539047A CN104274746A CN 104274746 A CN104274746 A CN 104274746A CN 201410539047 A CN201410539047 A CN 201410539047A CN 104274746 A CN104274746 A CN 104274746A
- Authority
- CN
- China
- Prior art keywords
- radix
- pharmaceutical composition
- pharyngitis
- preparation
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 52
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 230000001154 acute effect Effects 0.000 claims abstract description 4
- 208000016150 acute pharyngitis Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 241000628997 Flos Species 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004064 recycling Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000596154 Belamcanda Species 0.000 abstract 1
- 244000012254 Canarium album Species 0.000 abstract 1
- 235000009103 Canarium album Nutrition 0.000 abstract 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract 1
- 241000931705 Cicada Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 206010014025 Ear swelling Diseases 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of medicines and particularly relates to a pharmaceutical composition for treating pharyngitis, a preparation method of the pharmaceutical composition and a use of the pharmaceutical composition in preparation of a medicine for treating pharyngitis. The pharmaceutical composition provided by the invention comprises the following components: radix rehmanniae, wild chrysanthemum flower, radix ranunculi ternate, trigone, Chinese olive, radix ophiopogonis, astragalus, radix adenophorae, radix polygonati officinalis, blackberry lily, cicada slough and honeysuckle. The pharmaceutical composition has a good effect of treating pharyngitis and particularly acute/chronic pharyngitis, and the drug has a small toxic side effect, thereby being capable of being clinically promoted.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of pharmaceutical composition for the treatment of pharyngitis and preparation method thereof and treating the purposes in pharyngitis medicine with it.
Background technology
Pharyngitis is under pharyngeal mucosa, mucosa and adenoid diffuse inflammation, often with other upper respiratory disease, is a kind of disease of pharynx very common in crowd.Pharyngeal discomfort, has foreign body sensation, always feel pharyngeal have pharynx not under thing that can not tell again, irritative cough, dry, swell, block, pruritus etc., but seldom have pharyngalgia.The thickness expectorant block that often spues early morning easily causes nausea.According to theory of Chinese medical science, pharyngitis has acute and chronic dividing, but all belongs to " sore throat " category.
Chronic pharyngitis (Chronic pharyngitis) is mainly pharynx mucosa chronic inflammatory disease, and diffuse inflammation is often a part for upper respiratory tract other property inflammation chronic, and limitation inflammation is many inflammation with pharynx lymphoid tissue then.The chronic pharyngitis clinically course of disease is comparatively of a specified duration, generally more than three months, and often due to tired, catch a cold, the factor such as to suffer from cold causes exacerbation of symptoms, the dialectical common deficiency of YIN, the deficiency of vital energy or expectorant heat, time have wind, heat, expectorant, drink etc. concurrently, with heat-clearing and toxic substances removing, nourishing YIN and clearing away lung-heat, promote the production of body fluid moisturize, the method such as activating QI to eliminate phlegm is for controlling, a kind of commonly encountered diseases, frequently-occurring disease, in the Drug therapy of routine, more obstinate, and recurrent exerbation, flu increases the weight of, common with middle age.Show as pharyngeal mucosa chronic congestion.Pathological changes mainly concentrates on pharyngeal mucous layer, has more lymphoid tissue to infiltrate, also show leukocyte and plasmocyte infiltrating around its blood vessel.Connective tissue proliferation under mucosa and mucosa, can be loose with mucous gland, glandular secretion hyperfunctioning, and mucilage secretion increases and comparatively thickness.
To the treatment of pharyngitis patient, treatment may be a long-term process.If a people suffers from pharyngitis especially chronic pharyngitis, medication and prevention with for a long time, will will adhere to treatment for a long time, could effectively control and reduce advancing of disease, for the control of pharyngitis, except taking medicine on time, diet and living habit are also most important.
Summary of the invention
The invention provides a kind of pharmaceutical composition for the treatment of pharyngitis, this pharmaceutical composition good effect, toxic and side effects is little, and it is obtained by following raw material: the Radix Rehmanniae, Flos Chrysanthemi Indici, Radix Ranunculi Ternati, Rhizoma Sparganii, Fructus Canarii, Radix Ophiopogonis, the Radix Astragali, Radix Adenophorae (Radix Glehniae), Rhizoma Polygonati Odorati, Rhizoma Belamcandae, Periostracum Cicadae, Flos Lonicerae.
Pharmaceutical composition of the present invention on Chinese medicinal components is selected with removing toxic substances of dispeling the wind, relieving sore-throat by clearing away heat for main standard, carry out preferably to the parts by weight of above-mentioned all taste Chinese medicine, preferred condition be drug matching use afterwards medicine to the enhancing for the treatment of pharyngitis effect.Preferably, pharmaceutical composition of the present invention is obtained by the raw material of following weight portion: Radix Rehmanniae 4-13g, Flos Chrysanthemi Indici 11-15g, Radix Ranunculi Ternati 5.5-9.5g, Rhizoma Sparganii 1-8g, Fructus Canarii 10-30g, Radix Ophiopogonis 5-12g, Radix Astragali 10-18g, Radix Adenophorae (Radix Glehniae) 1-8g, Rhizoma Polygonati Odorati 10-18g, Rhizoma Belamcandae 1-3g, Periostracum Cicadae 8-16g, Flos Lonicerae 11-25g.As most preferred embodiment of the present invention, pharmaceutical composition of the present invention is obtained by the raw material of following weight portion: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
In order to express pharmaceutical composition of the present invention better, pharmaceutical composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparation such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule.Preferably, pharmaceutical composition of the present invention conveniently preparation technology be prepared into granule, tablet or capsule.
Present invention also offers a kind of preparation method of pharmaceutical composition described above, it mainly comprises following step: get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 6-8 times of soak by water twice, the time is respectively 1-3 hour, merge twice decocting liquid, filter, after cooling, adding ethanol to concentration is 40-80%, leave standstill 12-24 hour, reflux, extract, three times, return time is 2 ~ 3h, filter, filtrate recycling ethanol, is concentrated into extractum, and extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make clinical receptible various dosage form, to obtain final product.
The present invention also asks to protect the purposes of aforementioned pharmaceutical compositions in preparation treatment pharyngitis medicine, the purposes in especially acute in preparation treatment, chronic pharyngitis medicine.
The pharmacodynamics embodiment 10 of acute pharyngitis shows, compare with model group, high, medium and low three the dosage groups of pharmaceutical composition of the present invention all extremely significantly or can significantly reduce ear swelling value (the P < 0.01 of dimethylbenzene induced mice, P < 0.05), show that pharmaceutical composition of the present invention has the effect of the mice ear significantly suppressing dimethylbenzene induction, and there is significant dose-effect relationship to the reduction effect of ear swelling in it.Under same experiment condition, positive control drug also significantly reduces ear swelling value (P < 0.01), but its antiphlogistic effects is obviously not as good as pharmaceutical composition high dose group of the present invention.。
Strengthening the body resistance effect, the effect of moisturizing of promoting the production of body fluid: selecting the short secretion test of respiratory tract so as to the effect of moisturizing of promoting the production of body fluid is described, whether can increase sputum amount, can select the phenol red laboratory method of mice if observing tested medicine.Pharmacodynamics embodiment 11 of the present invention shows, compare with model group, pharmaceutical composition of the present invention each dosage group basic, normal, high all can significantly or pole significantly improve phenols contents (the P < 0.05 of mice trachea section, P < 0.01), show that pharmaceutical composition of the present invention has significant phlegm-dispelling functions, and there is significant dose-effect relationship.Under same experiment condition, positive control drug also pole significantly improves the phenols contents (P < 0.01) of mice trachea section.
Chronic pharyngitis Pharmacodynamics is studied, paper examines heat-clearing and toxic substances removing, the effect such as to moisturize of promoting the production of body fluid.Heat-clearing and toxic substances removing: with subacute, the chronic inflammation processes of cell proliferation for main experimental index, observes the effect of medicine.Pharmacodynamics embodiment 12 of the present invention shows, compare with model group, high, the middle dosage group of the present invention and aspirin matched group all extremely significantly can reduce granulomatous weight (P < 0.01), low dose group significantly reduces granulomatous weight (P < 0.05) and there is significant dose-effect relationship, this illustrates that pharmaceutical composition of the present invention can be obvious to therapeutic effect that is subacute, chronic inflammatory disease, especially high, the middle dosage of the present invention.
The present invention also have chosen the clinical of hospital and patient medical history carries out clinical trial, and treat acute pharyngitis patient 213 example altogether, total effective rate reaches 98.12%.Wherein criterion of therapeutical effect comprises following four aspects: fully recover for Clinical symptom and sign disappears, and recovers normal; Effective is that the basic or major part of Clinical symptom and sign disappears; Effectively for clinical symptoms is clearly better, but medication treatment need be continued; Invalid is that Clinical symptom and sign is without improvement.Instructions of taking: take tablet prepared by pharmaceutical composition of the present invention every day, each 1, every day 2 times, every sheet folding crude drug is about 0.10g, serve on 3 days.To 213 routine patients, adopt pharmaceutical composition of the present invention to carry out and followed the tracks for the treatment of.Wherein, cure 192 examples, effective 12 examples, effective 5 examples, invalid 4 examples, cure rate reaches 90.14%, and total effective rate is 98.12%, so pharmaceutical composition of the present invention is the active drug for the treatment of pharyngitis, there is good clinical meaning, have significant economic and social benefit.
Pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and toxic and side effects significantly reduce, and pharmaceutical composition effect of the present invention is comprehensive, and medication effect is better, significantly improve compliance and the quality of life of patient, there is significant clinical generalization value.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.
Embodiment 1
Prescription: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 7 times of soak by water twice, the time is respectively 2 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 60%, leaves standstill 24 hours, reflux, extract, three times, return time is 2h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet, to obtain final product.
Embodiment 2
Prescription: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 7 times of soak by water twice, the time is respectively 2 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 60%, leaves standstill 12 hours, reflux, extract, three times, return time is 3h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet capsule agent, to obtain final product.
Embodiment 3
Prescription: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 7 times of soak by water twice, the time is respectively 2 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 60%, leaves standstill 24 hours, reflux, extract, three times, return time is 3h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet and powder agent, to obtain final product.
Embodiment 4
Prescription: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 7 times of soak by water twice, the time is respectively 2 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 60%, leaves standstill 12 hours, reflux, extract, three times, return time is 2h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet powder, to obtain final product.
Embodiment 5
Prescription: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 7 times of soak by water twice, the time is respectively 2 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 60%, leaves standstill 24 hours, reflux, extract, three times, return time is 2h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet oral liquid, to obtain final product.
Embodiment 6
Prescription: Radix Rehmanniae 4g, Flos Chrysanthemi Indici 11g, Radix Ranunculi Ternati 5.5g, Rhizoma Sparganii 1g, Fructus Canarii 10g, Radix Ophiopogonis 5g, Radix Astragali 10g, Radix Adenophorae (Radix Glehniae) 1g, Rhizoma Polygonati Odorati 10g, Rhizoma Belamcandae 1g, Periostracum Cicadae 8g, Flos Lonicerae 11g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 8 times of soak by water twice, the time is respectively 3 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 80%, leaves standstill 24 hours, reflux, extract, three times, return time is 3h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet and powder agent, to obtain final product.
Embodiment 7
Prescription: Radix Rehmanniae 13g, Flos Chrysanthemi Indici 15g, Radix Ranunculi Ternati 9.5g, Rhizoma Sparganii 8g, Fructus Canarii 30g, Radix Ophiopogonis 12g, Radix Astragali 18g, Radix Adenophorae (Radix Glehniae) 8g, Rhizoma Polygonati Odorati 18g, Rhizoma Belamcandae 3g, Periostracum Cicadae 16g, Flos Lonicerae 25g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 6 times of soak by water twice, the time is respectively 1 hour, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 40%, leaves standstill 12 hours, reflux, extract, three times, return time is 2h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet tablet, to obtain final product.
Embodiment 8
Prescription: Radix Rehmanniae 13g, Flos Chrysanthemi Indici 11g, Radix Ranunculi Ternati 9.5g, Rhizoma Sparganii 1g, Fructus Canarii 30g, Radix Ophiopogonis 5g, Radix Astragali 18g, Radix Adenophorae (Radix Glehniae) 1g, Rhizoma Polygonati Odorati 18g, Rhizoma Belamcandae 1g, Periostracum Cicadae 16g, Flos Lonicerae 11g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 8 times of soak by water twice, the time is respectively 1 hour, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 40%, leaves standstill 24 hours, reflux, extract, three times, return time is 3h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet capsule agent, to obtain final product.
Embodiment 9
Prescription: Radix Rehmanniae 4g, Flos Chrysanthemi Indici 15g, Radix Ranunculi Ternati 5.5g, Rhizoma Sparganii 8g, Fructus Canarii 10g, Radix Ophiopogonis 12g, Radix Astragali 10g, Radix Adenophorae (Radix Glehniae) 8g, Rhizoma Polygonati Odorati 10g, Rhizoma Belamcandae 3g, Periostracum Cicadae 8g, Flos Lonicerae 25g.
Preparation technology:
Get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 6 times of soak by water twice, the time is respectively 3 hours, merges twice decocting liquid, filter, after cooling, adding ethanol to concentration is 80%, leaves standstill 12 hours, reflux, extract, three times, return time is 2h, filters, filtrate recycling ethanol, be concentrated into extractum, extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make tablet tablet, to obtain final product.
Embodiment 10 pharmaceutical composition xylol of the present invention causes the impact of mice ear
Get healthy ICR mice 50,18-22g, ♀ ♂ half and half, divide 5 groups, often organize 10, i.e. model group, positive controls (dexamethasone 20mg/kg), pharmaceutical composition of the present invention (obtaining by pharmaceutical composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group (dosage is 10mg/kg, 30mg/kg, 60mg/kg, all by crude drug gauge).Every ig administration 1 time/d, administration 14d, 60min after last medicine, mouse right ear uniform application dimethylbenzene 0.03mL/ only causes swollen, cuts ears and beat auricle and weigh after 2h, calculates ear swelling value (mg).Swelling value=auris dextra weight-left ear weight, the results are shown in Table 1.
The impact of table 1 pharmaceutical composition xylol of the present invention induced mice ear swelling (
n=10)
Note: compare with model group, * P < 0.05, * * P < 0.01
Result shows, compare with model group, high, medium and low three the dosage groups of pharmaceutical composition of the present invention all extremely significantly or can significantly reduce ear swelling value (the P < 0.01 of dimethylbenzene induced mice, P < 0.05), show that pharmaceutical composition of the present invention has the effect of the mice ear significantly suppressing dimethylbenzene induction, and there is significant dose-effect relationship to the reduction effect of ear swelling in it.Under same experiment condition, positive control drug also significantly reduces ear swelling value (P < 0.01), but its antiphlogistic effects is obviously not as good as pharmaceutical composition high dose group of the present invention.
Embodiment 11 pharmaceutical composition of the present invention promotes the production of body fluid on mice the impact of the effect of moisturizing
Get healthy ICR mice 50,18-22g, ♀ ♂ half and half, random point 5 groups, often organize 10, i.e. model group, positive controls (100% Radix Polygalae decocts night, 20mL/kg), pharmaceutical composition of the present invention (obtaining by pharmaceutical composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group (dosage is 10mg/kg, 30mg/kg, 60mg/kg respectively, all by crude drug gauge).Test each group of continuous ig administration 1 time/d, administration 7d, model group ig equal-volume normal saline.0.5h after last medicine, mouse peritoneal injects 5% phenol red normal saline solution 0.15mL/10g of fresh configuration, animal is put to death after injection phenol red solution 0.5h, after eye socket blood-letting, peel off trachea surrounding tissue, cut one section of trachea down to bronchus crotch from thyroid cartilage, jolting is also placed and is spent the night, obtain transparent supernatant, measure absorbance (μ g/mL) with 721 type spectrophotometer 546nm places, the results are shown in Table 2.
Table 2 pharmaceutical composition of the present invention on airway of mice phenols contents impact (
n=10)
Note: compare with model group, * P < 0.05, * * P < 0.01
Above-mentioned experimental result display, compare with model group, pharmaceutical composition of the present invention each dosage group basic, normal, high all can significantly or pole significantly improve phenols contents (the P < 0.05 of mice trachea section, P < 0.01), show that pharmaceutical composition of the present invention has significant phlegm-dispelling functions, and there is significant dose-effect relationship.Under same experiment condition, positive control drug also pole significantly improves the phenols contents (P < 0.01) of mice trachea section.
The impact that embodiment 12 pharmaceutical composition of the present invention swells on rat granuloma
Get cleaning grade Wistar rat 50, male and female half and half, body weight 190-210g, be divided into model group at random, (dosage is 10mg/kg, 30mg/kg, 60mg/kg to high, medium and low dosage group to pharmaceutical composition of the present invention (obtaining by pharmaceutical composition prescription described in embodiment 1 and preparation technology) respectively, all by crude drug gauge) and positive controls (aspirin 100mg/kg), often organize 10.
Model group rats etherization, cuts osculum at back, implants subcutaneous, skin suture immediately with ophthalmic tweezers by the sterilizing cotton balls being weighed as 10mg from minimal incision *.The all same modeling of other each test group, starts administration in operation, test each group of continuous 7d gastric infusion, every day 1 time next day.Model group is to equal-volume normal saline, rat is put to death in 8d, open former otch, cotton balls is taken out together with surrounding connective tissue, rejects fatty tissue, put 60 DEG C of oven dry 12h in baking oven, claim dry weight, deduct raw cotton ball quality and be granuloma net weight, the difference of granuloma net weight between more each group, experimental result is in table 3.
Table 3 pharmaceutical composition of the present invention on rat granuloma swell impact (
n=10)
Note: compare with model group, * P < 0.05, * * P < 0.01
Compare with model group, high, the middle dosage group of the present invention and aspirin matched group all extremely significantly can reduce granulomatous weight (P < 0.01), low dose group significantly reduces granulomatous weight (P < 0.05) and there is significant dose-effect relationship, this illustrates that pharmaceutical composition of the present invention can be obvious to therapeutic effect that is subacute, chronic inflammatory disease, especially high, the middle dosage of the present invention.
Claims (6)
1. treat the pharmaceutical composition of pharyngitis for one kind, it is characterized in that, it is obtained by the raw material of following weight portion: Radix Rehmanniae 4-13g, Flos Chrysanthemi Indici 11-15g, Radix Ranunculi Ternati 5.5-9.5g, Rhizoma Sparganii 1-8g, Fructus Canarii 10-30g, Radix Ophiopogonis 5-12g, Radix Astragali 10-18g, Radix Adenophorae (Radix Glehniae) 1-8g, Rhizoma Polygonati Odorati 10-18g, Rhizoma Belamcandae 1-3g, Periostracum Cicadae 8-16g, Flos Lonicerae 11-25g.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, it is obtained by the raw material of following weight portion: Radix Rehmanniae 9g, Flos Chrysanthemi Indici 13g, Radix Ranunculi Ternati 7.5g, Rhizoma Sparganii 5g, Fructus Canarii 20g, Radix Ophiopogonis 8g, Radix Astragali 14g, Radix Adenophorae (Radix Glehniae) 4g, Rhizoma Polygonati Odorati 14g, Rhizoma Belamcandae 2g, Periostracum Cicadae 12g, Flos Lonicerae 18g.
3. the pharmaceutical composition as described in claim 1,2, is characterized in that, it is granule, tablet or capsule.
4. a preparation method for pharmaceutical composition as claimed in claim 3, is characterized in that it comprises the following steps: get the 12 taste Chinese crude drugs such as the Radix Rehmanniae of recipe quantity and add 6-8 times of soak by water twice, the time is respectively 1-3 hour, merge twice decocting liquid, filter, after cooling, adding ethanol to concentration is 40-80%, leave standstill 12-24 hour, reflux, extract, three times, return time is 2 ~ 3h, filter, filtrate recycling ethanol, is concentrated into extractum, and extract dry becomes fine powder; Those skilled in the art technically add appropriate amount of auxiliary materials conventional formulation method in this preparation method and make clinical receptible various dosage form, to obtain final product.
5. the purposes of the pharmaceutical composition as described in claim 1,2 in preparation treatment pharyngitis medicine.
6. purposes as claimed in claim 5, it is characterized in that, described pharyngitis is acute or chronic pharyngitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410539047.5A CN104274746B (en) | 2014-10-14 | 2014-10-14 | Pharmaceutical composition for treating pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410539047.5A CN104274746B (en) | 2014-10-14 | 2014-10-14 | Pharmaceutical composition for treating pharyngitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104274746A true CN104274746A (en) | 2015-01-14 |
| CN104274746B CN104274746B (en) | 2017-05-24 |
Family
ID=52250407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410539047.5A Active CN104274746B (en) | 2014-10-14 | 2014-10-14 | Pharmaceutical composition for treating pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104274746B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606465A (en) * | 2015-03-05 | 2015-05-13 | 陈红 | Medicine for treating acute pharyngitis and preparation method for medicine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139062A (en) * | 2011-03-29 | 2011-08-03 | 权士珍 | Novel traditional Chinese medicine for treating pharyngitis and tonsillitis |
-
2014
- 2014-10-14 CN CN201410539047.5A patent/CN104274746B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139062A (en) * | 2011-03-29 | 2011-08-03 | 权士珍 | Novel traditional Chinese medicine for treating pharyngitis and tonsillitis |
Non-Patent Citations (2)
| Title |
|---|
| 严世芸等: "《中国中医药年鉴（学术卷）》", 31 December 2005 * |
| 解佳伟等: "中医药治疗慢性咽炎综述", 《山西大同大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606465A (en) * | 2015-03-05 | 2015-05-13 | 陈红 | Medicine for treating acute pharyngitis and preparation method for medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104274746B (en) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| CN102284049A (en) | Traditional Chinese medicine compound preparation for resisting ulcer and relieving chemoradiotherapeutic toxic and side effects, and preparation method and application thereof | |
| CN103494962B (en) | Traditional Chinese medicine composition capable of clearing heat and detoxifying | |
| CN101152354A (en) | Traditional Chinese medicine for treating acute dacryocystitis | |
| CN102068594A (en) | Chinese medicament for treating chronic prostatitis | |
| CN103495048A (en) | Traditional Chinese medicine composition for treating children's aphthous stomatitis | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN100509025C (en) | A medicine for treating diabetes | |
| CN102319376B (en) | Chinese herbal medicament for treating nephropathy | |
| CN104274746A (en) | Pharmaceutical composition for treating pharyngitis | |
| CN103877384B (en) | A kind of Chinese medicine preparation and preparation method who treats the carcinoma of the rectum | |
| CN106728447A (en) | The preparation method and application of Cheng forture paulownia root ethyl acetate extract | |
| CN101953937A (en) | Chinese medicament for treating chronic prostatitis | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN103599185B (en) | A kind of Chinese medicine composition being used for the treatment of headache | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN106620045A (en) | Preparation method and application of 95% ethanol extract of clerodendrum japonicum roots | |
| CN105582187A (en) | Traditional Chinese medicine composition formula for preventing and treating allergic dermatitis | |
| CN1422639A (en) | Dral medicine for treating rheumatism and atrophic diseases | |
| CN103611116A (en) | Traditional Chinese medicinal composition for treating vomiting of pregnancy | |
| CN103070998B (en) | Externally-applied plaster for curing pain of rheumatic joints | |
| CN103655875B (en) | Treatment blood sampling causes the medicine of Patients with Aplastic Anemia venous thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Qinghao Inventor after: Ma Chunhua Inventor before: Chen Hong |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170420 Address after: 362000 Huian County, Fujian City, the town of Hong Kong Road Applicant after: HUIAN LIKE TRADE CO.,LTD. Address before: 266000 Qingdao City, Sifang District, Shandong flood water ditch village, No. 2, 106 Applicant before: Chen Hong |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201102 Address after: Peng Lou Zhen Xi Jie, juancheng County, Heze City, Shandong Province Patentee after: Health center of Penglou Town, juancheng County Address before: 362000 Huian County, Fujian City, the town of Hong Kong Road Patentee before: HUIAN LIKE TRADE Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211116 Address after: 274000 No. 7, phase I, Shunwangcheng traditional Chinese medicine industrial park, juancheng County, Heze City, Shandong Province Patentee after: Shandong Huike Pharmaceutical Technology Co.,Ltd. Address before: 274609 Peng Lou Zhen Xi Jie, juancheng County, Heze City, Shandong Province Patentee before: Health center of Penglou Town, juancheng County |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating pharyngitis Effective date of registration: 20211229 Granted publication date: 20170524 Pledgee: Postal Savings Bank of China Limited juancheng County sub branch Pledgor: Shandong Huike Pharmaceutical Technology Co.,Ltd. Registration number: Y2021980017045 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230330 Granted publication date: 20170524 Pledgee: Postal Savings Bank of China Limited juancheng County sub branch Pledgor: Shandong Huike Pharmaceutical Technology Co.,Ltd. Registration number: Y2021980017045 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination for treating pharyngitis Granted publication date: 20170524 Pledgee: Shandong juancheng Rural Commercial Bank Co.,Ltd. Plaza sub branch Pledgor: Shandong Huike Pharmaceutical Technology Co.,Ltd. Registration number: Y2024980007729 |